ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Portfolio Strategies Channel
  2. Value Exists in Healthcare Sector
Portfolio Strategies Channel
Share

Value Exists in Healthcare Sector

Tom LydonApr 08, 2022
2022-04-08

Broadly speaking, the healthcare sector’s returns in 2022 are middling. In theory, that shouldn’t be the case because the group usually isn’t vulnerable to two of the scenarios plaguing markets today: high inflation and Russia’s war against Ukraine.

One way of interpreting the above is that there’s some value to had among healthcare equities and the related exchange traded funds, including the Invesco S&P 500 Equal Weight Health Care ETF (RYH A-). RYH isn’t setting the world ablaze this year, but it is performing less poorly than the S&P 500.

Fortunately, there is a valuation case for RYH along with some attractive fundamentals, which indicate that the equal-weight ETF could get its act together as 2022 moves forward.

“However, we continue to view the valuation in the sector as split between a general undervaluation in the larger biopharma group and an overvaluation in the device and diagnostics industries,” says Morningstar analyst Damien Conover. “While the biopharma valuations imply a high degree of risk involving potential changes in U.S. healthcare policies targeting drug prices, we see this threat as fading, especially as other priorities increase in the U.S. Further, the fundamental outlook for biopharma firms remains strong, with low patent exposure and several new innovative drugs launching and gaining market share.”

The $971.1 million RYH allocates about 26% of its combined weight to pharmaceuticals and biotechnology stocks. Regarding value opportunities, some critics assert that value tilts are the reason that equal-weight ETFs outperform.

That’s debatable, and specific to RYH, the fund devotes about 31.50% of its weight to stocks with the value designation. That’s by no means excessive, and is in fact below the nearly 34% it allocates to growth fare.

RYH is home to 67 stocks, including some that Morningstar’s Conover is bullish on. That group includes biotech giant Biogen (NASDAQ:BIIB).

“The market is overly concerned with the increasingly challenging outlook for Alzheimer’s drug Aduhelm, but Biogen is well positioned elsewhere. The firm leads the $20 billion global multiple sclerosis market with Avonex, Plegridy, Tysabri, and Tecfidera, and the launch of Vumerity partly protects the Tecfidera franchise from generic headwinds,” Conover notes.

Conover is also constructive on Zimmer Biomet Holdings (NYSE:ZBH), another RYH member firm.

“With the addition of smaller competitor Biomet, Zimmer is the undisputed king of large-joint reconstruction, by far. We expect favorable demographics, which include aging baby boomers and rising obesity, to fuel solid demand for large-joint replacement that should offset price declines,” notes the analyst.

For more news, information, and strategy, visit our Portfolio Strategies Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X